ABSTRACT
Background: Infantile hemangiomas are the most common benign soft tissue tumor of infancy and childhood occurring 4-10% of all infants. It is more frequent in premature children (23% of infants <1200g) and females (3:1 to 5:1). For many hemangiomas treatment is not required, however hemangioma in some locations need treatment to prevent complication. The Present study was done with an Aim to assess the efficacy and safety of oral Propranolol in management of infantile heamangioma in our set-up.Methods: This study was conducted from May 2016 to Nov 2017 at Department of Surgery and Pediatrics, M.L.B. Medical College, Jhansi after obtaining Ethical permission. Patients having confirmed were recruited & admitted for initiation of Oral Propranolol therapy for 5 days under the observation of Paediatrician. Oral Propranolol treatment was continued till the age of 11/2 years. A clinical assessment was made at each visit to the Outpatients Clinic every four weeks.Results: The incidences of infantile hemangioma were more in age group (0-7 months) i.e 55% (22 patients) followed by age group of (8-15 days) i.e. 30% (12 patients). As age advances presentation gradually decreases as after 30 days incidence is only 5%. Infantile hemangioma were more common in females’ patients (55% patients) & mostly 90% (36 patients) present as single lesion and only 10% (4 patients) present as multiple lesions. Most of hemangiomas presented as reddish in color 80% (32 patients) which reflected lesions are mostly superficial & only 10% were brownish red and 10% skin color indicated incidence of deeper penetration.Conclusion: Authors found that drug (Propranolol) to be effective even at low dose of 1mg/kg/day. In our study group it was effective and safe in almost all patients.
ABSTRACT
Background: Data comparing tapentadol with an antidepressant is limited. A comparison of tapentadol with mirtazapine at different dose has not been performed, the other antidepressant in the same therapeutic class with a significant market share, has been undertaken. In the absence of relevant data to assess the place that tapentadol should occupy in the therapeutic arsenal, indirect comparisons are the most rigorous way to go. We conducted a study evaluate antidepressant and analgesic activity of tapentadol with mirtazapine at different doses in Swiss albino mice. Methods: Tapentadol was administered at 10, 20 and 40 mg/kg (i.p) once daily for 14 days to swiss albino mice of either sex. The immobility period for antidepressant activity of mice were recorded in forced swim test and reaction time for analgesic activity of mice were recorded in tail flick test of the control and drug treated group. The antidepressant and analgesic activity of tapentadol (10, 20, 40 mg/kg i.p) was compared with that of mirtazapine (3, 5, 7 mg/kg i.p), administered for 14 days. Results: Tapentadol produced better antidepressant at (20, 40 mg/kg), but less at 10 mg/kg and significant analgesic activity at all the three doses, as indicated by reduction in immobility times and increase in reaction time as compared to control. Mirtazapine produced no antinociceptive activity at 3 mg/kg, but significant at 5, 7 mg/kg and showed better antidepressant activity at all the three doses in mice. The result of this study indicates the better analgesic activity of tapentadol at all the doses and least antidepressant activity at 10 mg/kg, as compared to mirtazapine which has shown better antidepressant activity at all the three doses but no analgesic activity at 3 mg/kg. Conclusion: It can be concluded that tapentadol is a better drug in case of depression associated with pain compared to mirtazapine in mice.